Avacta Therapeutics (AIM:AVCT) used two new data presentations to underline the tumour‑targeting strengths of its pre|CISION® platform, reporting that AVA6103 (FAP‑Exd) delivers higher and faster intratumoral payload exposure than a recreated dataset for the marketed ADC Enhertu®.
Preclinical work in multiple patient‑derived xenograft models — including tumours with very low FAP stromal expression — showed robust antitumour activity, the company highlighted. A synthetic comparator generated with AI to mirror AstraZeneca’s data revealed three pharmacokinetic advantages for AVA6103: quicker tumour penetration and payload release, tumour Cmax more than one log higher, and a Tumor Selectivity Index (AUCtumour/AUCplasma) roughly three times greater.
Clinical progress: AVA6103 entered the FOCUS‑01 Phase 1 trial with the first patient dosed in March. The multicentre dose‑escalation study will evaluate safety, tumour and plasma PK/PD and preliminary efficacy; colorectal cancer and hormone receptor‑positive breast cancer were added to the trial based on Tempus‑driven biomarker analysis.
An initial clinical readout is expected later this year.
Separately, Avacta (LSE:AVCT) presented first in vivo data for AVA6207, its dual‑payload pre|CISION® candidate, showing tumour‑selective release of a TOP1 inhibitor plus a DDR inhibitor, efficacy in a HER2+ gastric PDX with low FAP, and activity in models of TOP1i resistance (ATM‑deficiency and SLFN11 loss).
"The dual delivery mechanism of pre|CISION®shows its potential to dramatically increase the therapeutic window and reduce systemic toxicities, offering improved outcomes for patients with cancer," said Christina Coughlin, Chief Executive Officer
